
AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults
AbbVie (NYSE: ABBV) today announced that the European Commission has approved AQUIPTA® (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval…











